NASDAQ$BNTX
BioNTech SE-ADR · Q2 2026 earnings
Q2 2026 earnings · · Before market open · Investor relations
Briefing
BioNTech reported Q2 2026 revenues of €105.6 million and a net loss of €820.8 million.
BioNTech SE reported financial results for the second quarter ended June 30, 2026, showing a significant decline in revenues year-over-year due to lower COVID-19 vaccine demand. The company posted a widened net loss amid increased R&D and SG&A expenses, while maintaining a strong cash position of €16.6 billion. Guidance for full-year 2026 revenues was revised downward.
- Q2 2026 revenues €105.6 million vs. €260.8 million in Q2 2025
- Net loss widened to €820.8 million (€3.24 per share) from €386.6 million (€1.60 per share)
- Adjusted R&D expenses €477.1 million; adjusted SG&A €197.8 million
- Cash and securities €16.6 billion as of June 30, 2026; FY 2026 revenue guidance revised to €1.6-1.9 billion
Headline financials
Revenue & EPS history
BioNTech SE · Revenue · Quarterly
€122M
Forward guidance
Revised full-year 2026 guidance: revenues €1.6–1.9 billion, adjusted R&D €2.0–2.3 billion, adjusted SG&A €700–800 million.
Tailwinds
- Strong balance sheet supports pipeline investment
- Pipeline progress with multiple pivotal trials
Headwinds
- Softer COVID-19 vaccine demand
- Milestone revenues delayed
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
-0.4%
Avg return
Earnings day
+0.2%
Avg return
5 days after
+5.7%
Avg return
30 days after
39%
9 / 23 earnings
Positive
+13.8%
Q4 2020
Best reaction
-14.6%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2025 | -3.7% | -5.3% | -9.9% | |
| Q2 2025 | +2.5% | +4.0% | -6.4% | |
| Q4 2024 | -3.2% | -8.6% | -13.5% | |
| Q3 2024 | -0.5% | -0.8% | +2.9% | |
| Q1 2024 | -2.0% | -1.1% | +10.5% | |
| Q4 2023 | -2.3% | -1.2% | -7.8% | |
| Q3 2023 | +6.9% | +3.9% | +5.8% | |
| Q2 2023 | -4.4% | +0.4% | +12.8% | |
| Q1 2023 | -3.5% | -2.9% | +0.9% | |
| Q4 2022 | -4.1% | -2.8% | -13.7% | |
| Q3 2022 | +4.3% | +0.1% | +5.4% | |
| Q2 2022 | -14.1% | -12.4% | -21.3% | |
| Q4 2021 | -1.1% | +16.6% | +18.8% | |
| Q1 2022 | +6.1% | +16.6% | +18.8% | |
| Q3 2021 | -3.0% | -1.8% | +17.2% | |
| Q2 2021 | +7.1% | -3.0% | -13.6% | |
| Q1 2021 | +7.8% | +4.9% | +31.5% | |
| Q4 2020 | +13.8% | +10.8% | +38.9% | |
| Q3 2020 | +4.4% | +1.1% | +23.6% | |
| Q2 2020 | -6.5% | -7.2% | -17.2% | |
| Q1 2020 | -3.0% | -1.0% | -2.8% | |
| Q4 2019 | -14.6% | -14.9% | -23.4% | |
| Q3 2019 | +3.7% | +9.6% | +74.9% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro